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1. Introduction 
Immunostaining can be used to pinpont the subcellular localization of a protein antigen, to 
follow its changing position as cells respond to stumuli, or to compare its position to other 
proteins in the same cell. Using these methods one can follow an antigen’s distribution 
during development, mark the location of a particular cell type in a multicellular in vivo 
setting, or determine the presence of an antigen in a diseased tissue. The protocoles 
normally require multiple steps over several days as well as extensive knowledge of 
architecture of the tissues been studied. These procedures demand methods to preserve the 
structure of tissues, which unfortunately are often damaging to antigens. 
 The important propeties of the antibodies are; they specifically bind to a particular protein 
or molecule, that are called antigens. This binding property keeps the antibody binding 
unaltered in the physiological conditions. Also, any other noval antibodies could be made to 
other interested molecules. These are the crucial properties of the antibodies that are used in 
immunocytochemistry. An antigen is defined as a substance that can be bound by an 
antibody molecule through its antigen-binding sites, also called epitopes or antigenic 
determinants. Treatment of tissues with chemical fixatives and detergents can change the 
reactivity of proteins to antibodies because the exposure of epitopes to these chemicals can 
change the chemical and physical nature of the molecules in the epitope region. Many 
substances can, and are known to be antigenic, for example: proteins; nucleic acids: DNA, 
RNA; carbohydrates or sugar groups; lipids; small chemical groups; peptides (10-15 amino 
acids long). Thus antibodies can bind almost any repertoire of antigens, including chemicals 
and things B-cells have never encountered before.  
Development, characterization and manufacturing of antibodies has made tremendous 
progress in using the antibodies in many research, diagnostic, and therapeutic areas. 
However, it has been emphasized that antibodies both monoclonal and polyclonal remain 
the primary site in the vast majority of research and dianostic applications (Leduc and 
Connolly., 1955). New types of antibodies, recombinant and synthetic, have been developed 
and validated. Recombinated antibodies can be produced in transgenic mice (He et al., 
2002), also using bacteriophage (Hoogenboom and Chames., 2000) high quantities of high-
affinity antibodies can be produced. Synthetic antibodies (diabodies, triabodies, tetrabodies) 
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are generated using chemical or biological cross-linking to produce di-, tri-, and tetrameric 
multivalent conjugates exhibiting enhanced specifity and functional activity (Tomlinson and 
Holliger., 2000). There are some investigations on antibodies that have been made to replace 
amino acids by other biological molecules to ctreate chemical diversity and produce nucleic 
acid-based molecules forming specific binding to target antigens (Proske et al., 2005).  
Antibodies are the responsible proteins that hold the key step in immunocytochemistry. 
Antibodies have been used as research reagents for many years. Technology has improved 
and created new techniques and enhanced their value in immunocytochemistry. Antibody is 
tagged with a visible label. The visual marker which may be a fluorescent dye, colloidal 
metal, hapten, nanocrystal, radioactive marker or the more commonly in the light 
microscopic field, an enzyme. Experimental samples ranging from frozen sections, cell 
culture/suspension, to whole tissue samples have been used. Ideally, maximal signal 
strength along with minimal background is required to give optimal antigen demonstration. 
There are multiple ways of performing immunological stains on tissues, some of which 
include the direct method of staining, where the antibody is bound directly onto the antigen 
on a cell with a fluorescent or colored dye bound directly to the antibody. Another method 
includes the indirect method where the antigen is reacted with a primary antibody which 
binds directly. This is followed by a secondary antibody which binds to the primary 
antibody. Next, a tertiary reagent is applied, which binds to the secondary antibody, with an 
enzymatic end. When the quarternary reagent is applied, the enzymatic end of the tertiary 
reagent converts the substrate into a chromogen (DAB; Diaminobenzadine or others), which 
stains the cell, usually a brown color. 
 In the immunocytochemical application, since there are many different staining methods, 
the investigator should know how to optimize the staining method when the sataining fails. 
Fore example; there may be other methods that although using the same primary antibody 
concentrations, the degree of the staining intensity may be increased due to the method.  
Recommendations of the optimal dilutions of the primary antibody should be aquired. 
When the sataining does not work the investigators should have the basic nowledge to deal 
with the sepisific problem. In, particular, tissue fixation and tissue processing can have 
inportant effect on the antigenicity of the protein by changing the conformation of the 
epitope, therefore, creating non-specific background. Specificity of the antibodies needs to 
be tested in control experiments to avoid non-specific staining due to nonspecific binding to 
tissue components or binding to other proteins that share similar epitopes.  
2. Antibody molecules 
The antibodies, or immunoglobulins (Igs) are a group of glycoproteins present in the serum 
and tissue fluids. They are produced when the host’s lymphoid cells come into contact with 
immunogenic foreign molecules called antigens, and they bind specifically to the antigen 
which induced their formation.  
Each antibody molecule consists of four polypeptides– two heavy chains and two light 
chains joined to form a "Y" shaped molecule. Antibodies are further classified into multiple 
classes or isotypes. Five distinct classes of immunoglobulin molecule are recognized in most 
higher mamals, namely IgG, IgA, IgM, IgD and IgE (Table 1). These differ from each other in 
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size, charge, amino acid composition and carbohydrate content. In addition to the 
differences between classes the immunoglobulins within each class are also very 
heterogeneous.  
 
IgG;  Is the major immunoglobulin in normal human serum accounting for 70-
75% of the total immunoglobulin pool. It is distributed evenly between the 
intra- and extravascular pools, is the major antibody of secondary immune 
responses and the exclusive anti-toxin class. 
IgA; Represents 15-20% of the human serum immunoglobulin pool. In man 
more than 80% of IgA occurs as the basic four chain monomer but in most 
mammals the IgA in serum is mainly plymeric and occurs mostly as a 
dimer. It is the predominant immunoglobulin in sero-mucous secretions 
such as saliva, tracheobronchial secretions, colostrum, milk, and genito-
urinary secretions. 
IgM; Accounts for about 10% of the immunoglobulin pool. The molecule has a 
pentameric structure.This protein is largely confined to the intravascular 
pool and is the predominant “early” antibody frequently directed against 
antigenically complex infectious organisms. 
IgD; Accounts for less than 1% of the total plasma immunoglubulin but it is 
known to be present in large quantities on the membrane of many 
circulating B lymphocytes. It is involved in initial immune response 
IgE; Though a trace serum protein, is found on the surface membrane of 
basophils and mast cells in all individuals. This class may play a role in 
active immunity to parasites and commonly associated with immediate 
hypersensitivity reactions.  
Table 1. Ig classes 
Essentially each immunoglobulin molecule is bifunctional; one region of the molecule is 
concerned with binding to antigen while a different region mediates binding of the 
immunoglobulin to host tissues. IgG isotype is the immunoglobulin that is used in 
immunocytochemistry because it is generated in high quatities and its binding property is 
more consistent. Knowledge of the IgG structure (Fig. 1), is important in order to 
understand the mechanisms of the antibody and antigen reactions. The basic structure of 
IgG and all other immunoglobulin molecules is a unit consisting of two identical light 
polypeptide chains (variable region) and two identical heavy polypeptide chains (constant 
region) linked together by disulphide bonds. 
The class and subclass of an immunoglobulin molecule is determined by its heavy chain 
type. Thus the four IgG subclasses (IgG1, IgG2, IgG3 and IgG4) have heavy chains called γ1, 
γ2, γ3, and γ4 which differ only slightly although all are recognizable γ heavy chains. The 
differences between the various subclasses within an immunoglobulin class are less than the 
differences between the different classes; thus IgG1 is more closely related to IgG2, 3, or 4 
than to IgA, IgM, IgD or IgE. The amino acid sequence in the tips of the "Y" varies greatly 
among different antibodies. This variable region, composed of 110-130 amino acids, give the  
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Fig. 1. The antibody. An IgG antibody has a single constant region (C) and the variable 
region. The constant region containing light (CL) and heavy chain (CH) with the fragment 
crystallizable (Fc) region (effector region). The variable region contains the the antigen 
binding site. The small protein, only in the variable region, is known as the light chain; the 
large protein that is part of the constant and variable region is the heavy chain. The IgG can 
be digested by the protease enzyme, papain, into an Fc end (constant end) and a Fab end 
(variable end). 
antibody its specificity for binding antigen. The variable region includes the ends of the light 
and heavy chains. When the primary amino acid structure of a large number of light and 
heavy polypeptide chains is examined it is found that the variability between their V 
domains is not distributed evenly throughout the length of these regions. Some short 
polypeptide segments are termed hypervariable regions. It is now generally accepted that 
such hypervariable regions are involved directly in the formation of the antigen binding site. 
Hypervariable regions are sometimes referred to as Complementarity Determining Regions 
(CDR) and the intervening peptide segments as Framework Regions (FR). In both light and 
heavy chain three hypervariable regions exist – HV 1, 2 and 3. Four FR regions which have 
more stable amino acids sequences separate the HV regions. Treating the antibody with a 
protease can cleave this region, producing fragment antigen binding (Fab) that include the 
variable ends of an antibody. The constant region contains species specific sequences and 
the Fc portion that binds an Fc receptor, which is found on circulating white cells, 
macrophages, and natural killer cells. The Fc portion also has species-specific sites that are 
unique to the animal species in which the antibody was generated. Thus, generation of an 
antibody against IgG from rabbit will result in antibodies that bind the constant region from 
rabbit IgG only and not, for example, from mouse IgG.  
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Antibodies or IgG molecules are generated to other IgG molecules by injecting purified IgG 
molecules from one species into another species. In the case of mouse IgG injected into 
rabbit, it will produce rabbit anti-mouse IgG antibodies. Antibodies made against an IgG 
will only bind to the constant region or Fab region of the IgG. The variable end of the 
antibody contains the unique epitope-binding regions that give each antibody its specificity 
(Fig. 1). This variable region is the fraction antigen binding (Fab) portion. The unique 
configuration of the Fab specifically binds the epitope. When an antigen is injected into a 
rabbit, the resulting antibodies against the antigen have Fab portions that are unique to the 
antigen, but the rest of the IgG is similar to other IgG molecules. Each IgG antibody has two 
Fab ends, which can bind to two identical epitopes at the same time. The advantage of this 
bivalent epitope binding is that it can amplify the epitope detection.  
An antigen is a protein, peptide, or molecule used to cause an immune response in an 
animal. The animal responds by making antibodies to individual epitopes or antigenic 
determinant region located on the antigen. An individual antigen has multiple epitopes that 
can generate antibodies. An epitope can be an amino acid sequence on a denatured peptide 
or a several sequences on the surface of a folded protein. Animals frequently generate 
multiple antibodies to the same epitope. Also, an epitope on one protein might also exist on 
a different, unrelated protein because it has the same sequence or the same surface 
configuration. 
3. Producing antibodies 
When the macrophage engulf the bacteria, proteins (antigens) from the bacteria are broken 
down into short peptide chains and those peptides are then presented on the macrophage 
membrane attached to special molecules referred to as Major Histocompatibility Complex 
Class II (MHC II). Bacterial peptides are similarly processed and displayed on MHC II 
molecules on the surface of B lymphocytes. When a T lymphocyte determines the same 
peptide on the macrophage and on the B cell, the T cell stimulates the B cells. The stimulated 
B cell undergoes repeated cell divisions, enlargement and differentiation to form a clone of 
antibody producing plasma cells. Therefore, by recognizing a specific antigen, clonal 
expansion and differentiation of B cells to the plasma cells are acquired and all these cells 
start to produce the same specific antibody to only a single epitope. Epitopes are regions on 
an antigen that an antibody can bind to, and are also known as antigenic determinants. 
Epitopes can be: conformational; in which the antibody recognizes the secondary structure 
of the molecule, linear; in which the antibody binds to the determinant in both the denatured 
protein and the native protein; neoantigenic, which is an epitope which is not present in the 
native protein but becomes an epitope after the protein is cleaved by a protease. 
3.1 Polyclonal antibodies 
Polyclonal antibodies are multiple clones of antibodies produced to different epitopes of the 
antigen. In Fig. 2, the serum from an immunized rabbit contains antibodies from many 
clones of B-cells. In the rabbit serum, the different clones of antibodies have multivalent 
property, consisting of antibodies that bind to several regions (epitopes) of the antigen 
molecule, providing a strong dectecting capacity. This feature is important in that it gives 
high levels of staining for a single antigen. However, shared epitopes on different proteins 
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can label multiple proteins which can cause false evaluation, and it is referred to as cross-
reactivity.  
Polyclonal antibodies depend on a living animal thus if the animal dye no more antibody of 
that specific type can be produced. In addition, when a new animal is immunized with the 
same antigen, the exact epitopes generating antibodies will be different. An 
immunocytochemical study using a polyclonal antibody to detect IGF-I protein is 
demonstrated in Figure 3.  
 
Fig. 2. Schematic representation of the production of polyclonal antibodies. Polyclonal 
antibody preparations are usually a mixture of different specific antibodies known as 
“antibody clones”which all recognize the same antigen (A). The specificity difference means 
the antibodies bind to different epitopes on the antigen with different strength. The blood 
serum that is obtained from the rabbit that contains polyclonal antibodies is known as 
“antiserum”.  
 
  
Fig. 3. Photomicrographs of IGF-I immunoreactivity in the cortex. In the present 
immunostaining antihuman IGF-I polyclonal antibody is used to detect the IGF-I protein in 
various areas in the cortex. In the present study the siginificant decrease in density of IGF-I 
immunoreactive neurons in ethanol treated (B) compared to the control (A) rats. At a higher 
magnification neuronal processes are evident (inset). (Dalçik et al., 2009).  
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3.2 Monoclonal antibodies 
Monoclonal antibodies, originally from one mouse, contain a single antibody from one clone 
of B-cells to a single epitope on the antigen. This procedure was first described by Cesar 
Milstein, (Milstein et al., 1979; Milstein C., 1980). The antibodies are produced in mice (Fig. 
4), and when antibodies are produced, the spleen of the immunized mouse is removed. 
Then the spleen cells are dissociated. These spleen cells so-called the B-cells are fused with 
mouse myeloma cells in culture. The fusion process allows the hybrid cells to continue to 
proliferate. Each cell produces only one type of antibody. The procedure consists of 
screening the culture fluid from various clones for antibody via RIA, ELISA, or 
immunocytochemistry (Ritter M.A., 1986). One mouse spleen can give many different 
antibodies to different epitopes on the same antigen molecule. Antibodies spesific to 
fragments of the molecules could be produced in this way and, the culture can be stored 
until further production is required. Rabbit and mice monoclonal antibodies are available 
than other animals because good rabbit and mice myeloma cell lines are available.  
 
Fig. 4. Monoclonal Antibody production is the process by which large quantities of antibodies 
are produced. A mouse is immunized by injection of an antigen to stimulate the production of 
antibodies targeted against that particular antigen. The antibody forming cells are isolated 
from the mouse's spleen. Monoclonal antibodies are produced by fusing single antibody-
forming cells to tumor cells grown in culture. The resulting cell is called a hybridoma. Each 
hybridoma produces relatively large quantities of identical antibody molecules. By allowing 
the hybridoma to multiply in culture, it is possible to produce a population of cells, each of 
which produces identical antibody molecules. These antibodies are called "monoclonal 
antibodies" because they are produced by the identical cloned antibody producing cell. 
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The advantage of monoclonal antibodies compared to polyclonal antibodies is their absolute 
specificity for a single epitope on the antigen molecule, and different clones of antibodies 
can be generated to different epitopes on the same antigen. Therefore, since the cross-
reactivity is very much decreased the immunostaining can be clean without any artifacts on 
the slide. However, if the monoclonal antibody happens to bind to an antigenic sequence 
that is shared by other substance then in this case cross-reactivity will occur in the usage of 
monoclonal antibodies. Since the monoclonal antibodies bound to only one site on the 
molecule its binding results in weaker staining. In addition, since the specific sequence of 
the epitope may be altered with the fixation this may also cause no staining compared to the 
polyclonal antibodies because in polyclonal antiserum there are several regions (epitopes) in 
the antigen that the antibody can bind, if one region gets altered the others can be available. 
Therefore, in many cases frozen materials are been used rather than fixed paraffin sections. 
If using paraffin sections it may be wise to use many different antibodies spesific to different 
regions of the same antigen molecule to get better results.  
Although much work is required to generate monoclonal antibodies, with the aid of 
cultured hybridoma cells it can be generated indistinctly. However, polyclonal preparations 
are generally easier and less expensive to generate than monoclonal antibodies, and they can 
withstand greater variations in temperature and pH. An immunocytochemical study using a 
monoclonal antibody to detect IGF-I protein is depicted in Figure 5.  
 
 
Fig. 5. Photomicrograph showing IGF-I immunoreactivity from the placenta of the 
intrauterine growth retarded placental villus. In the present immunostaining anti-human 
IGF-I monoclonal antibody is used to detect the IGF-I protein in various areas in the 
placental villi. IGF-I immunoreactivity is observed in the stromal cells (sc) and capillary 
endothelial cells (Dalçik et al., 2001).  
sc 
    c 
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4. Selection of the antibody 
In the immunocytochemical applications the desired antibody used, is referred to as the 
“primary antibody”. There is also a “secondary antibody” to detect and bind to the primary 
antibody. The secondary antibodies usually have tag to make the primary-secondary antibody 
complex visible under the microscope. In order to detect a protein for example IGF-I protein in 
human tissue with anti-human rabbit polyclonal or anti-human mouse monoclonal antibody, 
it is appropriate to use an anti-rabbit secondary or anti-mouse secondary antibodies. This is 
followed by using either a horseradish peroxidase (HRP)-DAB (Fig. 4,5) or alkaline 
phosphatase-Vector Red reagents to produce a color in order to detect the localization of the 
desired antigen. Other colorimetric detection systems are also commercially available.  
Blocking reagents are used during the immunostaining procedure to avoid the problem of 
detecting endogenous immunoglobulins that are detected by the secondary antibody, in 
order to reduce the background staining. On the other hand, in the immunofluorescence 
technique the secondary antibodies are chemically conjugated with a fluorescent dye such as 
fluorescein isothiocyanate (FITC). There are two types of immunofluorescence staining 
methods; direct immunofluorescence staining and indirect immunofluorescence staining. In 
the direct immunofluorescence staining, the primary antibody is labelled with fluorescence 
dye and in the indirect immunofluorescence staining (Fig. 6) the secondary antibody is 
labelled with the fluorochrome (FITC or Texas Red). Immunofluorescence staining can be 
performed on cells that are fixed on slides and also tissue sections and these can be 
examined under a fluorescence microscope.   
 
Fig. 6. Photomicrograph showing nestin immunoreactivity from a 9 day old embryonic stem 
cells. In the present study mouse anti-nestin monoclonal antibody is used to detect the 
nestin protein which are the primary marker for the neuronal differentiation, and anti-
mouse IgM FITC is used for secondary antibody (Tas et al., 2007).  
5. Handling of the antibody 
Commonly the antibodies are commercially available. There are many companies that 
manufacture and sell antibodies. For example, antibodies may be sold in the form of 
hybridoma tissue culture supernatant, ascites fluid or crude serum. 
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It is important to get a good and efficeint antibody. Before obtaining the primary antibody, 
relevant work that has been done by other investigators should be examined thoroughly. In 
addition, recommendations from collegues that have used the antibody in their previous 
study is a good way to obtain a reliable antibody. After purchasing the antibody, one should 
read the product information and instructions in the datasheets provided by the supplier. 
The company supplies the antiserum in a liquid or powder form. Antibodies in powder 
form are liyophilized and transfered at room temperature. Antibodies in liquid form are 
transfered in ice packages.  
Antibodies should be stored as indicated by the vendor or supplier. When receiving the 
powder or liquid form of the antibody to prepare the stock solution it should be diluted and 
saved as small aliquots in microcentrifuge tubes at -20 0C or -70 0C. The aliquots should not 
be less than 10µl. When using the antiserum the antibody should be thawed, the left over 
antibodies should not be freezed again, repeated freezing and thawing is not recommended 
since these processes destroy the stability of the antibody. Damage can be reduced by 
adding glycerol to the solution. Extreme pH, and high salt environments can also damage 
the structure of the antibody. However, in some cases the antibodies are supplied as “ready 
to use” form. In this case, without diluting the antiserum it is applied directly on the tissue 
sections.   
When using the antibody it is note worthy to keep in mind that the antiserum can be 
contaminated by bacteria. The manufacturer supplies the antibody with a preserver substance 
such as sodium azide (NaN3). If there is a bacteria contamination it will be wise to discard the 
antibody and not use it, because the antiserum will create significant amount of background 
staining.  
A good antibody should have high affinity (binding strength) for its antigen. Therefore, they 
are not washed off the sections during the immunocytochemical staining. In addition, the 
concentration of the antibody is important to get clean appeareance of the tissue. A high 
dilution means decreased population of antibodies is present in the used antiserum and that 
unwanted antibodies are removed. Therefore, unwanted reactions are discarded. A low 
dilution means; increased population of antibodies is present in the used antiserum. The 
optimum dilution is required to get a better binding and staining, also to get low 
background staining (maksimum signal to noise ratio). High dilutions of the antibody are 
advantageous because they allow the total use of the available antibodies. If monoclonal 
antibodies are used in the immunocytochemical procedure, since the primary antibody is 
specific to the antigen, it is likely that unwanted reactions are absent, and therefore, the 
dilution in many cases becomes less important. Polyclonal antibodies come in as whole 
serum or as purified antibodies and an antibody concentration is given as µg/ml. The initial 
dilution of the monoclonal antibodies obtained via the hybridoma technology should be 
between 1:5-1:100. The secondary antibody used in the immunocytochemistry should be 
used at the optimum dilution such as; 1:200. The dilution propotion differ according to the 
type of tissue used and according to the tissue sections either paraffin or frozen section. The 
dilution is usually made commonly by phosphate buffered saline (PBS) solution. In order to 
obtain the working dilution (for example; 1:1000) the stock antibody is removed from the 
refrigerator, first 1:100 diluted solution is prepared than in the second step the solution is 
further diluted 10 times and 1:1000 working solution is prepared. The incubation period of 
the antibody with the tissue section in the antiserum can provide important information for 
the binding charecteristics of the antibody. Frequently, the incubation period of the antibody 
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with the sections at 37 0C is between 30 min. to 2 hour, at room temperature is 1-6 hour, at 
+4 0C is 6-24 hour.   
The methods where the antibody is used other than immunocytochemsitry (ICC) are; 
immunfluorescence (IF), western blot (WB), immunoblot (IB), immunoprecipitation (IP) and 
ELISA. 
6. Control application of the antibody 
It is important to make control studies in the immunocytochemistry procedures to make sure 
that the staining is specific. When the antibody targets a certain protein, the antibody should 
be unique to that particular protein. Before performing the study, other related protein family 
in the cell that may have homologous peptide sequence should be evaluated by identifing 
their aminoasid sequence. Because these proteins may cross react with the antibody and 
therefore, nonspecific binding and background staining may occur. The antibody specificity is 
best determined by immunoblot and or immunoprecipitation. The specificity of the method is 
best determined by preabsorption/preincubation control (Swaab et al., 1977; Willingham., 
1999), negative control, replacing the primary antibody with serum, and a positive control, 
using the antibody with cells known to contain the protein. In the preabsorption control, the 
antibody is mixed with the desired antigen (protein or peptide) before it is delivered to the 
sections. The goal of this process is to eliminate the binding of the antibody to the target 
protein. Therefore, when the antibody-protein complex at appropriate concentrations is 
applied to the tissue section, and if there is no staining then we can conclude that the antibody 
used is specific to that particular protein. We should also remember that the antibody can bind 
to any epitope of a protein that has the right conformation. Therefore, the competitive blocking 
experiment may produce a false data because, many peptides may bind nonspecifically to 
formalin-fixed tissues and can increase the immunostaining. Another test for antibody 
sensitivity and specificity is performing immunocytochemistry on negative control.  
7. Conclusion 
Immunocytochemistry is a technique that is used for staining cells or tissues using 
antibodies against target antigens or proteins. It is common to use unlabelled first antibody 
also referred to as the primary antibody, and then use the second antibody also referred to 
as secondary antibody directed against the first (anti-IgG). This secondary antibody is 
conjugated either with enzymes for colorimetric reactions, or fluorochromes, or gold 
particles (for EM) to visulaize the location of the antigen.  
In order to get best of the immunocytochemical technique the antibody used should have 
specificity, ability to reach and bind to the antigen. On the other hand, in the target antigen 
or protein epitope alterations can occur, and therefore weak staining will be visualized. The 
antibodies should be carefully selected. Search for specific antibodies and related protocols 
from the literture is necessary. Since monoclonal antibodies recognize single epitope they 
have greater specificty. However, polyclonal antibodies recognize multiple epitopes, and 
have increased risk of binding non-specific molecules with similar epitope. Thus, significant 
staining variations could occur according to different batches. Once receiving the antibody 
before using it in the immunocytochemical procedure, it should be tested at higher and 
lower concentrations in order to define the best dilution to study.  
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The book is coined to provide a professional insight into the different trends of immunoassay and related
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the use of bead-based assays and an overview on the laboratory assay systems. The book provides
technological innovations that are expected to provide an efficient channel for developments in
immunolabelled and related techniques. It is also most useful for researchers and post-graduate students, in
all fields, where immunolabelled techniques are applicable.
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